Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 2011-2020 of 3416 for cancer

Edit search filters
  1. Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

    Rochester, MN

  2. Study Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphomas Using Nivolumab with or without Varlilumab

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

    Rochester, MN

  4. Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. A Study of MR-Guided Laser Ablation of Prostate Bed Recurrences

    Rochester, MN

  6. A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

    Scottsdale/Phoenix, AZ, Rochester, MN

  7. A Study Using Targeted Inhibitors to Treat Specific Tumor Mutations in Patients with Meningiomas

    Jacksonville, FL, Rochester, MN

  8. Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures after Endotherapy

    Jacksonville, FL

  9. A Study of Screening Contrast-Enhanced Digital Mammography (CEDM) in Intermediate and High-Risk Patient Populations

    Scottsdale/Phoenix, AZ

  10. Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant

    Rochester, MN

.

Mayo Clinic Footer